Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Danaos Corporation (DAC) vs 10X Genomics Inc (TXG) Price & Performance

Danaos CorporationTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Danaos Corporation vs 10X Genomics Inc — how do they compare? Danaos Corporation trades at $171 (market cap $3.10B), while 10X Genomics Inc trades at $79.3 (market cap $10.07B). The key difference: 10X Genomics Inc is far larger — about 3.2× Danaos Corporation's market cap, and Danaos Corporation pays a 2.35% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaos Corporation for 25 Days and 10X Genomics Inc for 92 Days on average.

DACTXG
Market Cap
$3.10B$10.07B
Volume
286,0085,657,286
Sector
IndustrialsHealth
52-Week High
$170.22$97.74
52-Week Low
$84.05$11.48
Typical Hold Time
25 Days92 Days
Enterprise Value
$3.08B$9.59B
Dividend Yield
2.35%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Danaos Corporation

Danaos Corporation (DAC) trades at $164.48, down 0.88% on the day, with strong fundamental metrics including a low P/E of 5.57 and robust profitability margins. The stock shows a bullish technical trend, trading above key moving averages, with recent earnings consistently beating expectations. The company maintains strong cash flow generation and has declared multiple dividends, reflecting financial health and shareholder returns.

The outlook remains positive given DAC's undervaluation, earnings momentum, and dividend payments. Key risks include shipping industry cyclicality and global trade volatility. Analyst consensus is evenly split between Buy and Hold, indicating cautious optimism amid strong fundamentals and technical strength.

10X Genomics Inc

10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.

TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DAC

No sentiment data available yet.

TXG
4% Buy96% Sell
Avg holding period · 92 Days

Top news

Latest headlines on both assets

About Danaos Corporation

Danaos is a leading international owner of containerships, providing seaborne transportation services globally. It charters its fleet of vessels to major shipping lines across Asia, Europe, and the Americas.

Read more on DAC →

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG →